Amplia launches ovarian cancer trial for narmafotinib

Amplia Therapeutics initiates a clinical trial for its protein inhibitor narmafotinib, targeting ovarian cancer. The trial is conducted in partnership with the Australian New Zealand Gynaecological Oncology Group (ANZGOG). This development aims to advance treatment options for patients with this type of cancer.

Read the full story at Sydney Morning Herald→